Arrowhead Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Arrowhead Pharmaceuticals has a total shareholder equity of $173.7M and total debt of $273.7M, which brings its debt-to-equity ratio to 157.6%. Its total assets and total liabilities are $626.3M and $452.6M respectively.
Key information
157.6%
Debt to equity ratio
US$273.69m
Debt
| Interest coverage ratio | n/a |
| Cash | US$213.38m |
| Equity | US$173.71m |
| Total liabilities | US$452.57m |
| Total assets | US$626.29m |
Recent financial health updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Recent updates
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs
Nov 03Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?
Oct 09Financial Position Analysis
Short Term Liabilities: ARWR's short term assets ($237.9M) exceed its short term liabilities ($63.7M).
Long Term Liabilities: ARWR's short term assets ($237.9M) do not cover its long term liabilities ($388.8M).
Debt to Equity History and Analysis
Debt Level: ARWR's net debt to equity ratio (34.7%) is considered satisfactory.
Reducing Debt: ARWR's debt to equity ratio has increased from 0% to 157.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARWR has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ARWR is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.